share_log

Zhejiang Huakang Pharmaceutical Co., Ltd.'s (SHSE:605077) 7.7% Gain Last Week Benefited Both Retail Investors Who Own 43% as Well as Insiders

Zhejiang Huakang Pharmaceutical Co., Ltd.'s (SHSE:605077) 7.7% Gain Last Week Benefited Both Retail Investors Who Own 43% as Well as Insiders

浙江华康药业有限公司's (SHSE: 605077) 上周上涨7.7%,使持有43%的散户投资者和内部人士都受益
Simply Wall St ·  05/13 22:48

Key Insights

关键见解

  • The considerable ownership by retail investors in Zhejiang Huakang Pharmaceutical indicates that they collectively have a greater say in management and business strategy
  • The top 12 shareholders own 50% of the company
  • Insider ownership in Zhejiang Huakang Pharmaceutical is 41%
  • 散户投资者对浙江华康药业的大量所有权表明,他们在管理和业务战略中集体拥有更大的发言权
  • 前12名股东拥有公司50%的股份
  • 浙江华康药业的内部所有权为41%

Every investor in Zhejiang Huakang Pharmaceutical Co., Ltd. (SHSE:605077) should be aware of the most powerful shareholder groups. The group holding the most number of shares in the company, around 43% to be precise, is retail investors. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn).

浙江华康药业股份有限公司(SHSE: 605077)的每位投资者都应了解最强大的股东群体。持有该公司股份最多的集团是散户投资者,准确地说约为43%。也就是说,如果股票上涨,该集团将受益最大(如果股价下跌,则损失最大)。

Following a 7.7% increase in the stock price last week, retail investors profited the most, but insiders who own 41% stock also stood to gain from the increase.

继上周股价上涨7.7%之后,散户投资者获利最多,但拥有41%股票的内部人士也将从涨幅中获益。

In the chart below, we zoom in on the different ownership groups of Zhejiang Huakang Pharmaceutical.

在下图中,我们放大了浙江华康药业的不同所有权集团。

ownership-breakdown
SHSE:605077 Ownership Breakdown May 14th 2024
SHSE: 605077 所有权明细 2024 年 5 月 14 日

What Does The Institutional Ownership Tell Us About Zhejiang Huakang Pharmaceutical?

关于浙江华康药业,机构所有权告诉我们什么?

Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.

机构在向自己的投资者报告时通常会根据基准来衡量自己,因此,一旦股票被纳入主要指数,他们通常会对股票更加热情。我们预计大多数公司都会有一些机构在册,尤其是在它们正在成长的情况下。

Since institutions own only a small portion of Zhejiang Huakang Pharmaceutical, many may not have spent much time considering the stock. But it's clear that some have; and they liked it enough to buy in. So if the company itself can improve over time, we may well see more institutional buyers in the future. We sometimes see a rising share price when a few big institutions want to buy a certain stock at the same time. The history of earnings and revenue, which you can see below, could be helpful in considering if more institutional investors will want the stock. Of course, there are plenty of other factors to consider, too.

由于机构仅拥有浙江华康药业的一小部分股份,许多机构可能没有花太多时间考虑这只股票。但很明显,有些人有;他们很喜欢它,足以买进。因此,如果公司本身能够随着时间的推移而有所改善,那么将来我们很可能会看到更多的机构买家。当一些大型机构想同时购买某只股票时,我们有时会看到股价上涨。你可以在下面看到的收益和收入的历史可能有助于考虑是否会有更多的机构投资者想要这只股票。当然,还有很多其他因素需要考虑。

earnings-and-revenue-growth
SHSE:605077 Earnings and Revenue Growth May 14th 2024
SHSE: 605077 收益和收入增长 2024 年 5 月 14 日

We note that hedge funds don't have a meaningful investment in Zhejiang Huakang Pharmaceutical. Looking at our data, we can see that the largest shareholder is the CEO Deshui Chen with 16% of shares outstanding. Fujian Yake Food Co. Ltd is the second largest shareholder owning 6.1% of common stock, and Xinping Cheng holds about 5.6% of the company stock. Interestingly, the third-largest shareholder, Xinping Cheng is also a Member of the Board of Directors, again, indicating strong insider ownership amongst the company's top shareholders.

我们注意到,对冲基金没有对浙江华康药业进行有意义的投资。从我们的数据来看,我们可以看到最大股东是首席执行官陈德水,已发行股份的16%。福建雅客食品有限公司Ltd是第二大股东,拥有6.1%的普通股,程新平持有公司约5.6%的股份。有趣的是,第三大股东程新平也是董事会成员,这再次表明公司最大股东拥有强大的内部所有权。

After doing some more digging, we found that the top 12 have the combined ownership of 50% in the company, suggesting that no single shareholder has significant control over the company.

经过进一步的挖掘,我们发现排名前12位的公司合并所有权为50%,这表明没有一个单一股东对公司拥有重要的控制权。

While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. There is some analyst coverage of the stock, but it could still become more well known, with time.

虽然研究公司的机构所有权数据是有意义的,但研究分析师的情绪以了解风向哪个方向吹来也是有意义的。有一些分析师对这只股票的报道,但随着时间的推移,它仍可能变得更加广为人知。

Insider Ownership Of Zhejiang Huakang Pharmaceutical

浙江华康药业的内部所有权

The definition of an insider can differ slightly between different countries, but members of the board of directors always count. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it.

不同国家对内部人员的定义可能略有不同,但董事会成员总是计算在内。公司管理层经营业务,但首席执行官将向董事会负责,即使他或她是董事会成员。

Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.

当内部所有权表明领导层像公司的真正所有者一样思考时,内部所有权是积极的。但是,高度的内部所有权也可以赋予公司内部的一小部分人巨大的权力。在某些情况下,这可能是负面的。

It seems insiders own a significant proportion of Zhejiang Huakang Pharmaceutical Co., Ltd.. Insiders own CN¥2.2b worth of shares in the CN¥5.4b company. We would say this shows alignment with shareholders, but it is worth noting that the company is still quite small; some insiders may have founded the business. You can click here to see if those insiders have been buying or selling.

内部人士似乎拥有浙江华康药业有限公司的很大一部分股份。内部人士拥有这家54亿元人民币公司价值22亿元人民币的股份。我们可以说这表明了与股东的一致性,但值得注意的是,该公司仍然很小;一些内部人士可能已经创立了该公司。你可以点击这里查看这些内部人士是否在买入或卖出。

General Public Ownership

一般公有制

With a 43% ownership, the general public, mostly comprising of individual investors, have some degree of sway over Zhejiang Huakang Pharmaceutical. While this group can't necessarily call the shots, it can certainly have a real influence on how the company is run.

浙江华康药业拥有 43% 的所有权,公众对浙江华康药业有一定程度的影响力,主要是个人投资者。尽管这个群体不一定能做主,但它肯定会对公司的运作方式产生真正的影响。

Private Company Ownership

私人公司所有权

It seems that Private Companies own 12%, of the Zhejiang Huakang Pharmaceutical stock. It's hard to draw any conclusions from this fact alone, so its worth looking into who owns those private companies. Sometimes insiders or other related parties have an interest in shares in a public company through a separate private company.

私人公司似乎拥有浙江华康药业12%的股份。仅凭这一事实很难得出任何结论,因此值得研究谁拥有这些私营公司。有时,内部人士或其他关联方通过一家独立的私人公司对上市公司的股份拥有权益。

Next Steps:

后续步骤:

While it is well worth considering the different groups that own a company, there are other factors that are even more important. Be aware that Zhejiang Huakang Pharmaceutical is showing 2 warning signs in our investment analysis , and 1 of those is concerning...

尽管值得考虑拥有公司的不同群体,但还有其他因素更为重要。请注意,浙江华康药业在我们的投资分析中显示出两个警告信号,其中一个与...

But ultimately it is the future, not the past, that will determine how well the owners of this business will do. Therefore we think it advisable to take a look at this free report showing whether analysts are predicting a brighter future.

但归根结底,决定这家企业所有者的表现的是未来,而不是过去。因此,我们认为最好看一下这份免费报告,该报告显示了分析师是否预测了更光明的未来。

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

注意:本文中的数字是使用过去十二个月的数据计算得出的,这些数据是指截至财务报表日期当月最后一天的12个月期间。这可能与全年年度报告数据不一致。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发